Henning Blume

Summary

Affiliation: SocraTec R and D
Country: Germany

Publications

  1. ncbi [New guidelines for the assessment of bioavailability and bioequivalence]
    H Blume
    SocraTec R and D GmbH, Oberursel
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48:548-55. 2005
  2. ncbi Pharmacokinetic drug interaction profiles of proton pump inhibitors
    Henning Blume
    SocraTec R and D GmbH, Oberursel, Germany
    Drug Saf 29:769-84. 2006
  3. ncbi [Importance of the formulation for a chronopharmacologically optimised way of pain therapy. Results of a comparative bioavailability study of tramadol extended-release capsules after single-dose evening versus morning administration]
    A Warnke
    SocraTec R and D GmbH, Oberursel
    MMW Fortschr Med 150:36-42. 2008
  4. ncbi Characterization of the behavior of alginate-based microcapsules in vitro and in vivo
    M Anschütz
    SocraTec R and D, Oberursel, Germany
    Int J Clin Pharmacol Ther 47:556-63. 2009
  5. ncbi Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union
    M Wonnemann
    SocraTec R and D GmbH, Oberursel, Germany
    Int J Clin Pharmacol Ther 44:38-48. 2006
  6. ncbi Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources
    A Warnke
    SocraTec R and D GmbH, Oberursel, Germany
    Int J Clin Pharmacol Ther 47:405-12. 2009
  7. ncbi Workshop/conference report on EMA draft guideline on validation of bioanalytical methods
    Henning Blume
    SocraTec CSC GmbH, Oberursel, Germany
    Eur J Pharm Sci 42:300-5. 2011
  8. ncbi Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study
    Meinolf Wonnemann
    SocraTec R and D GmbH, Oberursel, Germany
    Clin Ther 30:48-58. 2008
  9. ncbi Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration
    M Anschütz
    SocraTec R and D, 61440 Oberursel, Germany
    Int J Clin Pharmacol Ther 48:158-70. 2010
  10. ncbi Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses
    Alexander Staab
    Zentrallaboratorium Deutscher Apotheker, Carl Mannich Str 20, 65760 Eschborn, Germany
    Eur J Pharm Sci 18:121-8. 2003

Collaborators

Detail Information

Publications12

  1. ncbi [New guidelines for the assessment of bioavailability and bioequivalence]
    H Blume
    SocraTec R and D GmbH, Oberursel
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48:548-55. 2005
    ..Comprehensive state-of-the-art guidance on the design, conduct and analysis of bioavailability and bioequivalence studies is given in the current European guideline...
  2. ncbi Pharmacokinetic drug interaction profiles of proton pump inhibitors
    Henning Blume
    SocraTec R and D GmbH, Oberursel, Germany
    Drug Saf 29:769-84. 2006
    ....
  3. ncbi [Importance of the formulation for a chronopharmacologically optimised way of pain therapy. Results of a comparative bioavailability study of tramadol extended-release capsules after single-dose evening versus morning administration]
    A Warnke
    SocraTec R and D GmbH, Oberursel
    MMW Fortschr Med 150:36-42. 2008
    ..Objective of this study was to investigate the rate and extent of tramadol bioavailability following evening versus morning administration...
  4. ncbi Characterization of the behavior of alginate-based microcapsules in vitro and in vivo
    M Anschütz
    SocraTec R and D, Oberursel, Germany
    Int J Clin Pharmacol Ther 47:556-63. 2009
    ..However, the application of functional excipients that are established in pharmaceutical applications is limited in case of food products, as they are typically not classified as Generally Recognized As Safe (GRAS)...
  5. ncbi Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union
    M Wonnemann
    SocraTec R and D GmbH, Oberursel, Germany
    Int J Clin Pharmacol Ther 44:38-48. 2006
    ..e. administration in the fasting state and administration with a meal, since the pharmacological and therapeutic actions of nifedipine are closely associated with the concentration...
  6. ncbi Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources
    A Warnke
    SocraTec R and D GmbH, Oberursel, Germany
    Int J Clin Pharmacol Ther 47:405-12. 2009
    ..Tramadol is currently one of the most frequently used opioid analgesics in the world...
  7. ncbi Workshop/conference report on EMA draft guideline on validation of bioanalytical methods
    Henning Blume
    SocraTec CSC GmbH, Oberursel, Germany
    Eur J Pharm Sci 42:300-5. 2011
    ..Intention of this Conference Report is to summarise important aspects of the discussions in order to draw certain conclusions, and to identify points which remain open and may require clarification at a later stage...
  8. ncbi Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study
    Meinolf Wonnemann
    SocraTec R and D GmbH, Oberursel, Germany
    Clin Ther 30:48-58. 2008
    ..The objective of this study was to compare the in vitro and in vivo characteristics of 2 nifedipine modified-release tablet formulations for once-daily dosing marketed in the European community, which were expected to be bioequivalent...
  9. ncbi Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration
    M Anschütz
    SocraTec R and D, 61440 Oberursel, Germany
    Int J Clin Pharmacol Ther 48:158-70. 2010
    ....
  10. ncbi Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses
    Alexander Staab
    Zentrallaboratorium Deutscher Apotheker, Carl Mannich Str 20, 65760 Eschborn, Germany
    Eur J Pharm Sci 18:121-8. 2003
    ..Using the suppository formulation led to a further reduction in rate (median of C(max) ratios: 30%, difference in median t(max) values: 3 h) and extent (42%) of bioavailability compared to the rectal solution...
  11. ncbi Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects
    Nassr Nassr
    ALTANA Pharma AG, 78467 Konstanz, Germany
    Br J Clin Pharmacol 63:365-70. 2007
    ..The aim of this study was to investigate the effects of roflumilast, an investigational PDE4 inhibitor for the treatment of COPD and asthma, on the pharmacokinetics of the CYP3A probe drug midazolam and its major metabolites...